Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019065791) HETEROCYCLIC COMPOUND
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/065791 International Application No.: PCT/JP2018/035827
Publication Date: 04.04.2019 International Filing Date: 27.09.2018
IPC:
C07D 487/10 (2006.01) ,A61K 31/407 (2006.01) ,A61K 31/424 (2006.01) ,A61P 21/00 (2006.01) ,A61P 25/00 (2006.01) ,A61P 25/08 (2006.01) ,A61P 25/14 (2006.01) ,A61P 25/16 (2006.01) ,A61P 25/22 (2006.01) ,A61P 25/24 (2006.01) ,A61P 25/28 (2006.01) ,A61P 29/00 (2006.01) ,A61P 43/00 (2006.01) ,C07D 498/10 (2006.01) ,C12N 9/99 (2006.01) ,C12N 15/52 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407
condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
424
condensed with heterocyclic ring systems, e.g. clavulanic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21
Drugs for disorders of the muscular or neuromuscular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
08
Antiepileptics; Anticonvulsants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
22
Anxiolytics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
24
Antidepressants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
10
Spiro-condensed systems
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
99
Enzyme inactivation by chemical treatment
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
52
Genes encoding for enzymes or proenzymes
Applicants:
武田薬品工業株式会社 TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 大阪府大阪市中央区道修町四丁目1番1号 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045, JP
Inventors:
鎌田 信 KAMATA, Makoto; JP
杉山 英之 SUGIYAMA, Hideyuki; JP
中村 実 NAKAMURA, Minoru; JP
村上 正鷹 MURAKAMI, Masataka; JP
池田 周平 IKEDA, Shuhei; JP
大川 友洋 OKAWA, Tomohiro; JP
徳原 秀和 TOKUHARA, Hidekazu; JP
Agent:
高島 一 TAKASHIMA, Hajime; JP
鎌田 光宜 KAMADA, Mitsunori; JP
Priority Data:
2017-19083829.09.2017JP
Title (EN) HETEROCYCLIC COMPOUND
(FR) COMPOSÉ HÉTÉROCYCLIQUE
(JA) 複素環化合物
Abstract:
(EN) Provided is a compound which has an MAGL inhibitory effect and is expected to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis, etc.), anxiety disorders, pains (e.g., inflammatory pain, cancer pain, neuropathic pain, etc.), epilepsy, depression and the like. The present invention pertains to a compound represented by formula (I): [wherein each symbol is as described in the description] or a salt thereof.
(FR) L'invention fournit un composé qui possède une action inhibitrice de MAGL, et qui est prévu pour être avantageux en tant qu'agent de prévention ou de traitement contre les maladies neurodégénératives (par exemple, la maladie d'Alzheimer, la maladie de Parkinson, la chorée de Huntington, la sclérose latérale amyotrophique, le traumatisme crânien, le glaucome, la sclérose en plaques, ou similaire), les troubles de l'anxiété, la douteur (par exemple, les douleurs inflammatoires, les douleurs cancéreuses, les douleurs neurales, ou similaire), l'épilepsie, la dépression, ou similaire. Plus précisément, l’invention concerne un composé représenté par la formule (I) (Dans la formule, chaque symbole est tel que défini dans la description.), ou un sel de celui-ci.
(JA) MAGL阻害作用を有し、神経変性疾患(例、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、外傷性脳損傷、緑内障、多発性硬化症など)、不安障害、疼痛(例、炎症性疼痛、癌性疼痛、神経性疼痛など)、てんかん、うつ病などの予防または治療剤として有用であると期待される化合物を提供する。 本発明は、式(I):[式中の各記号は明細書に記載の通りである。] で表される化合物またはその塩に関する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)